Your response concerning ebola is well taken - however, the performance of this stock has been, at best, frustrating. There was a run up to $8.00 per share earlier this year, but after some slightly disappointing news in the 2nd quarter, the price dropped below $4.00 per share. Additionally, FDA "approval" keeps getting pushed back (now were expecting it in 1st quarter 2015).
News about the company and the product and technology it is developing has been in general consistently good - but this has not translated into the share prices increasing - and I find myself wondering why this is...
Market Data 
Markets 
AI
